As of 2025-04-28, the Relative Valuation of Fulcrum Therapeutics Inc (FULC) is (3.03) USD. This relative valuation is based on P/E multiples. With the latest stock price at 3.53 USD, the upside of Fulcrum Therapeutics Inc based on Relative Valuation is -185.9%.
The range of the Relative Valuation is (2.62) - (3.15) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 14.5x - 17.5x | 16.6x |
| Forward P/E multiples | 14.5x - 18.0x | 17.0x |
| Fair Price | (2.62) - (3.15) | (3.03) |
| Upside | -174.1% - -189.1% | -185.9% |
| Date | P/E |
| 2025-04-25 | -19.59 |
| 2025-04-24 | -19.48 |
| 2025-04-23 | -19.93 |
| 2025-04-22 | -20.26 |
| 2025-04-21 | -19.21 |
| 2025-04-17 | -18.26 |
| 2025-04-16 | -16.98 |
| 2025-04-15 | -16.87 |
| 2025-04-14 | -16.21 |
| 2025-04-11 | -14.93 |
| 2025-04-10 | -14.57 |
| 2025-04-09 | -15.99 |
| 2025-04-08 | -14.65 |
| 2025-04-07 | -15.10 |
| 2025-04-04 | -13.93 |
| 2025-04-03 | -14.15 |
| 2025-04-02 | -15.71 |
| 2025-04-01 | -15.32 |
| 2025-03-31 | -15.99 |
| 2025-03-28 | -16.71 |
| 2025-03-27 | -17.15 |
| 2025-03-26 | -16.76 |
| 2025-03-25 | -17.26 |
| 2025-03-24 | -17.82 |
| 2025-03-21 | -17.48 |
| 2025-03-20 | -16.76 |
| 2025-03-19 | -16.49 |
| 2025-03-18 | -16.76 |
| 2025-03-17 | -17.32 |
| 2025-03-14 | -17.32 |
| 2025-03-13 | -16.10 |
| 2025-03-12 | -16.82 |
| 2025-03-11 | -16.43 |
| 2025-03-10 | -16.49 |
| 2025-03-07 | -17.43 |
| 2025-03-06 | -17.87 |
| 2025-03-05 | -18.04 |
| 2025-03-04 | -18.15 |
| 2025-03-03 | -17.98 |
| 2025-02-28 | -19.93 |
| 2025-02-27 | -18.71 |
| 2025-02-26 | -18.43 |
| 2025-02-25 | -20.54 |
| 2025-02-24 | -20.54 |
| 2025-02-21 | -21.37 |
| 2025-02-20 | -21.37 |
| 2025-02-19 | -21.31 |
| 2025-02-18 | -20.93 |
| 2025-02-14 | -20.48 |
| 2025-02-13 | -20.59 |